The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Talquetamab for patients with RRMM: Updated results from the MonumenTAL-1 trial
|
The phase I/II MonumenTAL-1 trial (NCT03399799, NCT04634552) assessed the safety and efficacy of talquetamab, a GPRC5D/CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).1 Results from this trial, which were previously reported by the Multiple Myeloma Hub, led to the approval of talquetamab by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of patients with RRMM who have received ≥4 or ≥3 lines of therapy, respectively. Updated efficacy and safety results from three cohorts of patients from the MonumenTAL-1 trial – 0.4 mg/kg weekly (QW), 0.8 mg/kg biweekly (Q2W), and patients with prior T-cell redirected therapy (TCR) – with a longer median follow-up and including additional patients were presented at the European Hematology Association (EHA) 2024 Hybrid Congress by Rasche.1 |
| Key learnings: |
|
With a longer follow-up, the overall response rates in MonumenTAL-1 were 74%, 70%, and 67% in the QW, Q2W, and prior TCR cohorts, respectively. |
|
Patients continued to experience durable responses, particularly patients with a complete response or better (≥CR); in the QW and Q2W cohorts, the median durations of response were 9.5 months and 17.5 months, respectively, and 28.6 months and not reached, respectively, among patients with ≥CR. |
|
The median progression-free survival was 7.5 months, 11.2 months, and 7.7 months, and the 24-month overall survival rates were 60.6%, 67.1%, and 57.3% in the QW, Q2W, and prior TCR cohorts, respectively. |
|
The safety profile of talquetamab was consistent with previous results, with no new safety signals observed. |
|
These findings support the use of talquetamab for the treatment of patients with RRMM. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
